Colin Kellaher. By
Pfizer Inc. and Beam Therapeutics Inc. said on Monday that they have formed an exclusive four-year research collaboration focused on in-vivo base editing programs for three targets aimed at rare genetic diseases of the liver, muscle and central nervous system.
As part of the collaboration, New York-based drugmaker Pfizer will make an advance payment of $300 million to the Cambridge, Mass., biotechnology company Beam.
The companies said Beam is also eligible for up to $1.05 billion in potential milestone payments, assuming Pfizer exercises its opt-in license rights for all three targets, along with royalties on product sales.
The companies said Beam will conduct all research activities through development candidate selection for three undisclosed targets that are not included in Beam’s current programs, while Pfizer can opt for exclusive, worldwide licenses for each candidate, After which it will be responsible for all development. activities, as well as potential regulatory approval and commercialization.
Write to Colin Kellaher at [email protected]